C07K 14/23
From brucella
Official title: from Brucella (G)
C07K14/23 (From brucella) appears on 15 US grants and 16 published applications in this corpus.
Search patents in C07K- Granted patents
- 15
- Published applications
- 16
- Assignees
- 14
- Inventors
- 59
- Latest grant
- 23 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 1 |
| 2002 | 1 | 1 |
| 2003 | 0 | 2 |
| 2004 | 1 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 0 | 2 |
| 2008 | 1 | 0 |
| 2009 | 0 | 0 |
| 2010 | 1 | 1 |
| 2011 | 3 | 1 |
| 2012 | 0 | 2 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 1 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 1 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 1 | 1 |
| 2024 | 0 | 1 |
| 2025 | 0 | 1 |
| 2026 | 1 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Fusion protein comprising BP26 and antigenic polypeptide23 Jun 2026US 12,662,515 B2Korea Advanced Institute of Science and Technology
- Recombinant Escherichia coli and application thereof in screening erythritol-producing strains28 Feb 2023US 11,591,374 B2Jiangnan University
- Adjuvant for vaccines, vaccines that comprise said adjuvant and uses thereof6 Dec 2016US 9,511,137 B2Consejo Nacional De Investigaciones Cientificas Y Tecnicas
- Artificial chimeras engineered to simulate multiple biological threat agents13 Sep 2011US 8,017,330 B1The United States of America as represented by the Secretary of the Army
- Artificial chimeras engineered to simulate multiple biological threat agents9 Aug 2011US 7,993,844 B1The United States of America as represented by the Secretary of the Army
- Brucellosis cell immune protein and use thereof25 Sep 2025US 2025/0298035 A1Tecon Biopharmaceutical Co., Ltd.
- A multiplex assay for the diagnosis of brucella canis infection4 Apr 2024US 2024/0110913 A1Cornell University
- Fusion protein comprising bp26 and antigenic polypeptide17 Aug 2023US 2023/0257426 A1Korea Advanced Institute of Science and Technology
- Recombinant Escherichia Coli and Application Thereof in Screening Erythritol-producing Strains15 Oct 2020US 2020/0325185 A1Jiangnan University
- Adjuvant for vaccines, vaccines that comprise said adjuvant and uses thereof11 Oct 2012US 2012/0258145 A1Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet)
Most cited
By later US patents
- Live vaccine against Brucellosis14US 6,444,445 B2The United States of America as represented by the Secretary of the Army · 2002
- Mutants of Brucella melitensis7US 5,939,075 AThe United States of America as represented by the Secretary of the Army · 1999
- 17-KDA Brucella abortus antigen, recombinant polypeptides, nucleic acids coding for the same and use thereof in diagnostic and prophylactic methods and kits5US 6,296,855 B1Innogenetics N. V. · 2001
- Immunogenic compositions including rough phenotype Brucella host strains and complementation DNA fragments4US 7,416,878 B2The United States of America as represented by the Secretary of the Army · 2008
- Recombinant Brucella abortus gene expressing immunogenic protein3US 5,023,174 AIowa State University Research Foundation, Inc. · 1991